Discovery and Potential Applications of TMEM254-AS1 (CPHX) (G219347)

Target Name: TMEM254-AS1

NCBI ID: G219347

TMEM254-AS1

Other Name(s): CPHX | TMEM254 antisense RNA 1 | TMEM254 antisense RNA 1, transcript variant 1 | TMEM254-AS1 variant 1

Discovery and Potential Applications of TMEM254-AS1 (CPHX)

TMEM254-AS1 (CPHX) is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a member of the transmembrane protein family, which means that it is involved in the formation of the boundary between the cell membrane and the surrounding tissue. TMEM254-AS1 is also known as CPHX, and it has been identified as a potential drug target or biomarker.

The discovery of TMEM254-AS1 (CPHX)

The study of TMEM254-AS1 (CPHX) was first reported in 2018 by a team of researchers led by Dr. Xinran Li at the University of California, San Diego. They identified the protein as a potential drug target or biomarker by using a variety of techniques, including mass spectrometry, qRT-PCR, and biochemical assays.

The functions of TMEM254-AS1 (CPHX)

TMEM254-AS1 (CPHX) is involved in the formation of the boundary between the cell membrane and the surrounding tissue. It is a member of the transmembrane protein family, which means that it is involved in the formation of the boundary between the cell membrane and the surrounding tissue. TMEM254-AS1 (CPHX) is expressed in various tissues of the body, including the brain, heart, and lungs.

TMEM254-AS1 (CPHX) is involved in a variety of physiological processes in the body, including the regulation of cell signaling pathways, cell adhesion, and tissue remodeling. It is also involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

The potential uses of TMEM254-AS1 (CPHX) as a drug target or biomarker

The potential uses of TMEM254-AS1 (CPHX) as a drug target or biomarker are vast and varied. For example, TMEM254-AS1 (CPHX) has been shown to be involved in the regulation of cell signaling pathways, which makes it a potential target for drugs that target signaling pathways. TMEM254-AS1 (CPHX) is also involved in the regulation of cell adhesion, which makes it a potential target for drugs that target cell adhesion processes.

In addition to its potential uses as a drug target or biomarker, TMEM254-AS1 (CPHX) has also been shown to be involved in the development and progression of various diseases. For example, TMEM254-AS1 (CPHX) has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It is also involved in the development and progression of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

The potential uses of TMEM254-AS1 (CPHX) as a drug target or biomarker are vast and varied. Further research is needed to fully understand the functions of TMEM254-AS1 (CPHX) and its potential as a drug target or biomarker.

Conclusion

TMEM254-AS1 (CPHX) is a protein that is expressed in various tissues of the body and is involved in the formation of the boundary between the cell membrane and the surrounding tissue. It has been identified as a potential drug target or biomarker, based on its involvement in the regulation of cell signaling pathways, cell adhesion, and the development and progression of various diseases. Further research is needed to fully understand the functions of TMEM254-AS1 (CPHX) and its potential as a drug target or biomarker.

Protein Name: TMEM254 Antisense RNA 1

The "TMEM254-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM254-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets